High dose melphalan for refractory myeloma--the M.D. Anderson experience.
Barlogie
B
B
University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Department of Hematology, Houston 77030.
Dicke
K A
KA
Alexanian
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D013781:Texas; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone; D008558:Melphalan